Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook.
Mediafeed on MSN
Semaglutide showdown: Pills or shots—Which is right for you?
This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...
According to the latest results from Gallup’s survey, self-reported obesity has started to fall, declining by nearly 3 points ...
It might sound shocking to read about such drastic actions, but it’s stories of overweight children being bullied and too ...
US-based pharma giant Eli Lilly’s blockbuster weight-loss drug, Mounjaro, is set to expand its reach across India through a ...
Denmark's Novo Nordisk said Tuesday it would replace more than half of its board, including the chair, as the Ozempic and Wegovy maker restructures in the face of rising competition for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback